Granules Consumer Health, Llc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Granules Consumer Health, Llc Pharmaceutical Import Records from India — 2 Products, $2.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Granules Consumer Health, Llc — Pharmaceutical Importer Profile (2026) | 2 Products, $2.4M Trade | TransData Nexus

Granules Consumer Health, Llc

Pharmaceutical Importer · United States · Analgesics & Antipyretics Focus · $2.4M Total Trade · DGFT Verified

Granules Consumer Health, Llc is a pharmaceutical importer based in United States with a total trade value of $2.4M across 2 products in 2 therapeutic categories. Based on 47 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Granules Consumer Health, Llc sources from 2 verified Indian suppliers, with Granules India Limited accounting for 92.5% of imports.

Granules Consumer Health, Llc — Import Portfolio & Supplier Network

Granules Consumer Health, Llc import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Granules Consumer Health, Llc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Granules India Limited	$1.2M	27	92.5%
Granules Life Sciences Private Limited	$100.0K	2	7.5%

Granules Consumer Health, Llc sources from 2 verified Indian suppliers across 26 distinct formulations.

What Formulations Does Granules Consumer Health, Llc Import?

Formulation	Value	Ships
Acetaminophen rapid release gelcaps 500MG (apap rr gel 500MG) (gray)	$100.0K	2
Guaifenesin extended release tablets 600MG	$91.9K	2
Loratadine tablets USP 10MG	$81.1K	2
Acetaminophen rapid release gelcaps 500MG (grey)	$50.0K	1
Acetaminophen extended release tablets USP 650MG (17028x2x200's Pack)	$50.0K	1
Acetaminophen extended release tablets USP 650MG (8376x2x200's Pack)	$50.0K	1
Extra strength acetaminophen USP 500MG caplets (8724 pac)	$50.0K	1
Extra strength acetaminophen USP 500MG	$50.0K	1
Guaifenesin extended release tablets 600MG (7536x500's Pack)	$50.0K	1
Acetaminophen extended-release tablets USP 650MG (49392x100's Pack)	$50.0K	1
Mucus relief ggf er 1200MG (32640x4x14's Pack)	$50.0K	1
Acetaminophen rapid release gelcaps 500MG (gray) (19,880 pac)	$50.0K	1
Acetaminophen extended release tablets USP 650MG (46080x225's Pack)	$50.0K	1
Extra strength acetaminophen USP 500MG caplets (8,760 pac)	$50.0K	1
Mucus relief ggf er 1200MG 4x14sgch-samsclub/usa-pc569 (16,140 pac)	$50.0K	1

Granules Consumer Health, Llc imports 26 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Acetaminophen	Analgesics & Antipyretics	$2.1M	43	0.6%	13
2	Guaifenesin	Respiratory & OTC	$200.0K	4	0.7%	16

Granules Consumer Health, Llc imports 2 pharmaceutical products across 2 categories into United States totaling $2.4M.

Granules Consumer Health, Llc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Granules Consumer Health, LLC is a U.S.-based pharmaceutical importer specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Headquartered in Manassas, Virginia, the company operates as a wholly-owned subsidiary of Granules Pharmaceuticals, Inc., which is itself a subsidiary of Granules India Limited. Granules Consumer Health serves as the front-end division for over-the-counter (OTC) products in the U.S., leveraging Granules India's manufacturing efficiencies and integrated supply chain to deliver high-quality, cost-effective generic pharmaceuticals to major U.S. retailers.

The company's role in the U.S. pharmaceutical distribution network is pivotal, focusing on the importation and distribution of finished dosage forms. By sourcing products from Granules India's facilities, Granules Consumer Health ensures a steady supply of generic medications, contributing to the availability of affordable healthcare options in the U.S. market. This strategic positioning allows the company to meet the growing demand for generic OTC products while maintaining stringent quality and regulatory standards.

2Distribution Network

Granules Consumer Health operates a centralized distribution model from its facility in Manassas, Virginia. This location serves as the primary hub for packaging and distributing pharmaceutical products imported from India. The facility is equipped with advanced packaging lines capable of processing controlled substances and OTC products, ensuring compliance with U.S. Food and Drug Administration (FDA) regulations. The company's logistics capabilities are designed to efficiently manage the importation and distribution of pharmaceutical products across the United States, ensuring timely delivery to major retailers and healthcare providers.

3Industry Role

In the U.S. pharmaceutical supply chain, Granules Consumer Health functions primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from Granules India Limited, the company plays a crucial role in introducing generic OTC products to the U.S. market. This position enables Granules Consumer Health to bridge the gap between Indian pharmaceutical manufacturing and U.S. consumer demand, facilitating the availability of affordable generic medications. The company's focus on finished formulations distinguishes it from raw material suppliers, positioning it as a key player in the distribution of generic pharmaceuticals within the U.S. market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Granules Consumer Health, Llc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Granules Consumer Health's sourcing strategy exhibits a high degree of concentration, with 92.5% of its imports from India originating from Granules India Limited. This single-source dependency suggests a strategic choice to leverage the manufacturing efficiencies and integrated supply chain of its parent company. The stability of this relationship is evidenced by the consistent importation of finished pharmaceutical formulations, including acetaminophen and guaifenesin, over the past four years. However, this concentration also presents potential risks, such as supply chain disruptions or regulatory changes affecting the sole supplier. Diversifying the supplier base could mitigate these risks and enhance supply chain resilience.

2Supply Chain Resilience

Granules Consumer Health's supply chain resilience is closely tied to the operations of Granules India Limited. The company's reliance on a single supplier for finished pharmaceutical formulations may expose it to risks associated with supply chain disruptions, such as production delays or regulatory challenges in India. The absence of backup suppliers and limited formulation diversity further accentuates this vulnerability. To bolster resilience, Granules Consumer Health could consider establishing relationships with additional suppliers and expanding its product portfolio to include a broader range of formulations. Ensuring that all suppliers adhere to Good Manufacturing Practice (GMP) standards recognized by the FDA is essential to maintain product quality and regulatory compliance.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation, distribution, and marketing of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which sets forth requirements for drug approval, labeling, and manufacturing practices. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating new drugs and ensuring that imported pharmaceuticals meet U.S. standards for safety, efficacy, and quality. For Indian generics to enter the U.S. market, they must undergo the FDA's Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the reference listed drug.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the U.S. are stringent, necessitating that all imported drugs be approved by the FDA. Manufacturers and distributors must comply with Good Manufacturing Practice (GMP) standards recognized by the FDA, ensuring that products are consistently produced and controlled according to quality standards. The FDA conducts inspections to verify compliance with these standards. For instance, Granules Consumer Health's packaging facility in Manassas, Virginia, underwent a GMP inspection by the FDA in December 2025, resulting in zero observations, underscoring the company's commitment to regulatory excellence.

Granules Consumer Health, Llc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Granules Consumer Health's focus on analgesics and antipyretics, particularly acetaminophen, aligns with the high demand for pain relief and fever reduction medications in the U.S. market. The inclusion of respiratory and OTC products, such as guaifenesin, addresses the need for treatments for common cold and cough symptoms. By importing these specific therapeutic categories, Granules Consumer Health meets consumer demand for effective and affordable OTC medications, leveraging the manufacturing capabilities of Granules India Limited to provide high-quality products.

2Sourcing Profile

Granules Consumer Health's sourcing strategy is centered on generic drug formulations, primarily acetaminophen and guaifenesin, sourced from Granules India Limited. This focus allows the company to offer cost-effective alternatives to brand-name medications, catering to the price-sensitive segment of the U.S. market. India's established pharmaceutical manufacturing sector, with its adherence to FDA-recognized GMP standards, makes it a strategic partner for Granules Consumer Health in fulfilling its procurement needs.

3Market Positioning

Seller's Guide — How to Become a Supplier to Granules Consumer Health, Llc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Granules Consumer Health's supply chain by offering competitive pricing, reliable delivery schedules, and adherence to FDA-recognized GMP standards. Diversifying the supplier base could mitigate risks associated with single-source dependency and enhance supply chain resilience. Additionally, expanding the product portfolio to include a broader range of formulations could meet the evolving needs of the U.S. market and strengthen Granules Consumer Health's competitive position.

2Requirements & Qualifications

Indian exporters seeking to supply Granules Consumer Health and the U.S. market must obtain FDA approval for their products, demonstrating compliance with FDA-recognized GMP standards. Manufacturers must provide comprehensive stability data and bioequivalence studies to support the ANDA process. Additionally, adherence to labeling requirements, including English language labels and serialization mandates, is essential to meet regulatory standards.

3How to Approach

Frequently Asked Questions — Granules Consumer Health, Llc

What products does Granules Consumer Health, Llc import from India?

Granules Consumer Health, Llc imports 2 pharmaceutical products across 2 categories. Top imports: Acetaminophen ($2.1M), Guaifenesin ($200.0K).

Who supplies pharmaceuticals to Granules Consumer Health, Llc from India?

Granules Consumer Health, Llc sources from 2 verified Indian suppliers. The primary supplier is Granules India Limited (92.5% of imports, $1.2M).

What is Granules Consumer Health, Llc's total pharmaceutical import value?

Granules Consumer Health, Llc's total pharmaceutical import value from India is $2.4M, based on 47 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Granules Consumer Health, Llc focus on?

Granules Consumer Health, Llc imports across 2 categories. The largest: Analgesics & Antipyretics (91.5%), Respiratory & OTC (8.5%).

Get Full Granules Consumer Health, Llc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.